INTRODUCTION
Chimeric antigen receptor (CAR) T cells constitute a highly promising adoptive immunotherapy for cancer. CAR T cells directed against CD19 have shown remarkable clinical results in heavily pretreated patients with relapsed or refractory lymphoid malignancies, including pediatric 1,2 and adult 3, 4 acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), 5, 6 and other non-Hodgkin's lymphoma (NHL). [7] [8] [9] [10] Development of CARs for treatment of other hematologic malignancies or solid tumors is ongoing. 11 Anti-CD19 CAR T cells have been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The University Hospital Heidelberg initiated the first investigator-initiated trial (IIT) for CAR T cell therapy in Germany. The Heidelberg Chimeric Antigen Receptor T Cell Trial Number 1 (HD-CAR-1; European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] no. 2016-004808-60; ClinicalTrials.gov: NCT03676504) is a monocentric, open-label, prospective phase I/II trial initiated in September 2018 with in-house leukapheresis as well as CAR T cell manufacturing for treating adult and pediatric ALL, adult CLL, and NHL patients with autologous T lymphocytes transduced with a third-generation CAR vector (RV-SFG.CD19.CD28.4-1BBzeta) targeting CD19. 12 Due to the fact that CAR T cells are considered genetically modified organisms (GMOs), they constitute gene therapy medicinal products (GTMPs). Hence, CAR T cells are manufactured according to good manufacturing practice (GMP) standards. Regulatory authorities require extensive safety evaluation of advanced therapy medicinal products (ATMPs), i.e., cellular immune therapies, such as CAR T cells. To warrant safety, transgene copies within a CAR T cell product, i.e., vector copy numbers (VCNs), have to be assessed prior to patient administration. Additionally, response to CAR T cell treatment is associated with expansion, 6 as well as persistence of CAR T cells in treated patients. 10, 13 Therefore, the assessment of CAR T cell levels in patients at different time points after CAR T cell administration is crucial for deciding on further patient therapies. CAR VCN assessment in CAR T cell products and monitoring CAR T cells in the peripheral blood (PB) of treated patients are usually performed via quantitative PCR (qPCR). [14] [15] [16] [17] . Here, we propose a duplex (DP) qPCR strategy based on a single-copy gene (SCG; SCG-DP-PCR), i.e. ribonuclease (RNase)P RNA component H1 gene (RPPH1; RNaseP in the following) (single copy per haploid human genome), for accurate and robust determination of VCN in CAR T cell products and in PB samples of treated patients. SCG-DP-PCR was compared to the absolute standard curve singleplex (SP) qPCR approach (absolute standard curve method [ACM]) and validated within the framework of HD-CAR-1.
RESULTS
Method validation and evaluation of SCG-DP-PCR were performed as follows: efficiencies and correlation coefficients (R 2 ) of PCR reactions within the duplex PCR (targeting the CAR transgene and SCG) were compared before similar efficiencies over the relevant transgene copy number range were confirmed. A final proof of similar efficiencies was achieved by the use of an efficiency control (EC) sample (description in Materials and Methods) as a direct testing method. Following this method validation, VCNs in healthy donor samples were assessed via ACM and SCG-DP-PCR, and both methods were directly compared. Subsequently, SCG-DP-PCR was applied on follow-up samples of patients treated with HD-CAR-1 CAR T cells. Differences and influencing factors of ACM and SCG-DP-PCR were determined.
Efficiencies and Linearity of PCR Reactions (ACM and SCG-DP-PCR)
For method validation, efficiency and linearity (correlation coefficient) of PCR reactions of ACM (SP-CAR) and SCG-DP-PCR (DP-CAR, DP-RNaseP) were assessed by linear regression analysis of standards. Standard curves were only considered valid if a R 2 of above 0.98 and mean efficiencies of 100% ± 10% were achieved. SP-CAR PCR reaction displayed an efficiency of 103.5 ± 7.1%; efficiencies of 104.2 ± 2.1% and 99.3 ± 1.6% were achieved for DP-CAR and DP-RNaseP PCR reactions, respectively (Table 1) .
Standard curves were generated for SP-CAR, DP-CAR, and DP-RNaseP in three validation experiments. Figure 1 illustrates the results obtained in one of three validation experiments.
Relative Efficiency Plot of SCG-DP-PCR
The relative efficiency plot compared simultaneous PCR reactions over the tested transgene copy number range by calculation of comparative threshold cycle (DCt; DP-CAR À DP-RNaseP) and graphical analysis (semi-logarithmic display; transgene copies [log10]: x axis; DCt: y axis). Figure 2 displays generated relative efficiency plots. DCt (DP-CAR À DP-RNaseP) in the DP-PCR standards was similar for the 4 higher copy standards (3 Â 10 2 À 3 Â 10 5 copies/ reaction). The smallest standard (30 copies/reaction) was excluded from analysis due to high standard deviation in replicates. Consequently, diagnostic measuring range for this method setup was defined within 3 Â 10 2 À 3 Â 10 5 copies/reaction. In this range, the slope of the regression curve was 0.0168.
Efficiency Control Sample
The EC sample was added to every duplex PCR experiment. The calculated DCt values (DP-CAR À DP-RNaseP) in this control sample ranged between Ct R À0.31 and Ct % 0.17. The application of 2 ÀDCt (DP-CAR À DP-RNaseP) , acceptable copy numbers of the CAR transgene relative to RNaseP gene of 0.89, 1.06, and 1.24 (1.06 ± 0.18) was achieved ( Table 2 ). The amplification plot of the EC sample from one validation experiment ( Figure S1 ; Supplemental Materials and Methods) illustrates similarity of the CAR transgene and RNaseP gene amplifications in the SCG-DP-PCR setup.
Vector Copy Numbers
VCNs were obtained by mathematical extrapolation of regression curves to sample signals via ACM and by relative SCG-DP-PCR applied. The application of SCG-DP-PCR on CAR T cell samples generated from healthy donors, an increase of 0.8 ± 0.2 VCN/cell, was observed when compared to ACM (Table 3) .
CAR T Cell Monitoring in Patients Using a Validated SCG-DP-PCR
Following validation on healthy donor-derived CAR T cells, SCG-DP-PCR was also used to assess CAR T cell expansion in HD-CAR-1 patient samples. Figure 3 displays CAR T cell expansion CAR-transduced T cells in clinical practice are mostly generated by the use of viral vectors. These vectors originate from the Orthoretrovirinae subfamily of Retroviridae, i.e., g-retrovirus and lentivirus. They convert their RNA genome into cDNA and integrate this genetic information into the genome of the target cell, thus enabling longterm transgene expression. However, the use of viral vectors for CAR T cell manufacturing for therapeutic purposes requires strict biosafety testing. The exclusion of the presence of replication-competent retrovirus (RCR) within CAR T cell samples, as well as evaluation of the average number of integrated vector copies per transduced T cell, is mandatory. A variety of different strategies for VCN determination have been used, relying mainly on ACM, 14 as well as relative quantification approaches. [15] [16] [17] . ACM is associated with potential inaccuracies, due to the need of standard curves. Figure 4 , right.
The validation of SCG-DP-PCR was performed by testing the following: (1) the efficiency and linearity of PCR-reactions, (2) the constancy of PCR efficiencies within the relevant transgene copy range, and (3) the similarity of PCR efficiencies, as well as RNaseP SCG status, by using an EC sample and applying the 2 ÀDCt method.
SCG-DP-PCR reactions displayed similar efficiencies close to 100% and almost optimal linearities (R 2 > 0.98) ( Table 1 ; Figure 1 ). Constant PCR efficiencies over the relevant concentration range, i.e., similar DCt (DP-CAR À DP-RNaseP) in every duplex standard sample, were confirmed by a relative efficiency plot. Here, log10 copies (x axis) were plotted against DCt (DP-CAR À DP-RNaseP) (y axis). Via linear regression, a slope of <0.1 (optimal 0) was obtained, proving constancy (Figure 2 ). Efficiency validation was completed, verifying similar amplification efficiencies of DP-CAR and DP-RNaseP PCR reactions and confirming the SCG status of RNaseP using the EC sample. CAR transgene copies relative to the RNaseP gene of 0.89, 1.06, and 1.24 (1.06 ± 0.18) for the EC sample were achieved, lying within our accepted range (Table 2; Figure S1 ). Consequently, we established a relative qPCR approach that is independent from a calibrator sample. RNaseP could be detected in all samples we assessed. In the unlikely case of a missing RNaseP signal, a repetition of the PCR reaction is highly advised.
After validation, SCG-DP-PCR was compared to ACM by measuring VCN of CAR T cells generated from healthy donors ( Table 3) . For SCG-DP-PCR, a higher VCN 0.8 ± 0.2/cell was assessed when compared to ACM. We assume that via ACM VCN might be under-represented due to the influence of differing reaction conditions within an experimental setup with standard samples (standard curve; no genomic DNA) and GMO samples (target sample; genomic DNA).
Additional factors, such as well-to-well variations or errors in DNA concentration measurement, influence ACM results. Moreover, sequential dilution of standards, as well as mathematical extrapolation, affects ACM and might contribute to observed VCN variations. However, underlying reasons for VCN discrepancy of ACM and SCG-DP-PCR were not analyzed any further. In SCG-DP-PCR, reactions are performed within one well. Hence, a main technical requirement for SCG-DP-PCR is the use of highly efficient and compatible primer and probe sets targeting the CAR transgene and the SCG. Methodical differences and influencing factors on ACM and SCG-DP-PCR are summarized in Table 4 . SCG-DP-PCR was subsequently applied on HD-CAR-1 patient samples achieving clinical relevant data on CAR T cell expansion ( Figure 3) . No CAR T cells could be detected in samples of peripheral blood in patient 2. Given that the patient displayed a partial response to treatment, CAR T cells might have accumulated at the cancer cell site without circulating into the peripheral blood.
Overall, validated SCG-DP-PCR represents a less error-prone method to address the regulatory safety release criterion VCN in CAR T cell products compared to ACM. It is highly suitable to follow up CAR T cells in the peripheral blood of patients. Additionally, RNaseP represents an internal control for every PCR reaction of patient samples. Our main aim, to develop a suitable approach for standardization of VCN assessment in the field of clinical CAR therapy, was achieved. Importantly, the lack of standardized detection methods for the monitoring of CAR T cells or other GMOs in patients post-treatment could be overcome by SCG-DP-PCR. Moreover, given the lack of a calibrator sample, this relative quantification approach can be easily transferred and established in other laboratories. Subsequently, the important ability to monitor the expansion of CAR T cells or other GMOs in patients could be extended to many hospitals. This might improve the assessment of the course of diseases of patients in the field of gene therapy, particularly CAR T cell therapy.
MATERIALS AND METHODS

Manufacturing of CAR T Cells
Clinical-grade CAR T cells were produced in the GMP Core Facility of our institution from healthy donors, as well as from patients enrolled in the HD-CAR-1 trial. Standardized CAR T cell 
Isolation of PBMCs
PBMCs containing CAR T cells from healthy donors and HD-CAR-1 patient PB samples were isolated by Ficoll density gradient (Linaris, Dossenheim, Germany) and genomic DNA extracted (cat. #51104, QIAamp DNA Blood Mini; QIAGEN). DNA concentration was measured by UV spectroscopy (NanoDrop OneC; Thermo Fisher Scientific, Applied Biosystems). Samples were diluted to a final concentration of 20 ng/mL in nuclease-free H 2 O.
qPCR Methods SCG-DP-PCR and ACM qPCR were performed on genomic DNA derived from PBMCs. To determine the number of integrated CD19.CD28.4-1BBzeta copies in CAR T cells, i.e., VCN, 100 ng genomic DNA isolated from patients and healthy-donor PBMCs For SCG-DP-PCR VCN calculation, the 2 ÀDCt method, based on the previously described 2 ÀDDCt method, 19 was used. The mathematical evaluation of experimentally generated qPCR data applying SCG-DP-PCR using the 2
ÀDCt method or via ACM is described in detail within the Supplemental Materials and Methods A.
The following primer sets were used for SCG-DP-PCR reactions:
(1) Sequences of forward, reverse primer, and probe targeting the CAR transgene were used, as described before for the SP-CAR qPCR (ACM). (2) RNaseP: Copy Number Reference Assay, RNaseP (cat. #4403326, TaqMan; Applied Biosystems), containing RNaseP gene-specific forward primer, reverse primer, and probe (VIC/TAMRA) within a reaction mix.
Besides NTC, a biological negative control, as well as the RV-SFG.CD19.CD28.4-1BBzeta plasmid as a positive control, an EC sample was included within each experiment for SCG-DP-PCR validation to verify similar amplification efficiencies of CAR transgene and RNaseP. The EC sample consisted of genomic DNA from a nontransduced cell sample (comprising RNaseP) combined with the RV-SFG.CD19.CD28.4-1BBzeta plasmid in a 1:1 ratio. Calculations for EC sample generation and preparation are described within the Supplemental Materials and Methods. Besides testing similar PCR efficiencies, the EC sample verifies the SCG status of RNaseP in genomic DNA when a VCN of 1 is achieved.
The accepted range for DCt (DP-CAR À DP-RNaseP) in the EC sample was defined per calculation between DCt R À0.4 and DCt % 0.56. Application of 2 ÀDCt (DP-CAR À DP-RNaseP) results in an accepted variance for the copy number of 1 ± 0.32 for Ct values of DP-CAR relative to DP-RNaseP.
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